Abstract Title Author List Session

ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human phase I study

J Bendell, M Patel, J Infante, C Kurkjian, S Jones, S Pant, H Burris, J Hainsworth, O Moreno, K Moore

October 20 12:30-3:00pm A17 Poster Session A: Apoptosis, Necrosis, and Autophagy

Exhibit Hall C-DActivity of the TORC 1/2 kinase inhibitor, CC-223, in hormone receptor positive (HR+) breast cancer cell lines and patients (pts) with genetically characterized HR+ breast cancer in a Phase I clinical trial

M M Mita, HT Arkenau, JC Bendell, PN Munster, A Mahipal, J P Delord, LG Paz-Ares, JC Soria, S Xu, T Tran, T Shi, X Wu, R Chopra, K Hege, A Varga

October 20 12:30-3:00pm A68 Poster Session A: Clinical Trials

Exhibit Hall C-D

Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer

M Patel, J Infante, KN Moore, M Keegan, A Poli, M Padval, SF Jones, J Horobin, HA Burris III

October 20 12:30-3:00pm A69 Poster Session A: Clinical Trials

Exhibit Hall C-DA Phase Ib study of CC-486 (Oral Azacitidine) as a priming agent for carboplatin or NAB-paclitaxel in subjects with relapsed and refractory solid tumors

P LoRusso, D Rasco, J Bendell, J Sachdev, R Ramanathan, G Weiss, P Munster, WJ Edenfield, K Liu, A Blackwood-Chirchir, J DiMartino, DD Von Hoff

October 20 12:30-3:00pmA120 Poster Session A: Epigenetic Targets

Exhibit Hall C-DA phase 1 pharmacokinetic/pharmacodynamic (PK/PD) study of the sachet formulation of the oral dual PI3K-mTOR inhibitor BEZ235 given twice daily (BID) in patients (pts) with advanced solid tumors

J Bendell, C Kurkjian, J Infante, T Bauer, HA Burris III, D Spigel, D Yardley, F Greco, K Shih, D Thompson, S Jones

October 20 12:30-3:00pmA166 Poster Session A: mTOR/PI3-Kinase

Exhibit Hall C-D

Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors

G Shapiro, R Kristeleit, M Middleton, HA Burris III, L Rhoda Molife, J Evans, R Wilson, P LoRusso, J Spicer, V Dieras, M Patel, E Dominy, D Simpson, H Giordano, AR Allen, SS Jaw-Tsai, R Plummer

October 20 12:30-3:00pmA218 Poster Session A: Pharmacokinetics and

Pharmacodynamics Exhibit Hall C-D

A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers

JC Bendell, AW Tolcher, SF Jones, M Beeram, JR Infante, P Larsen, K Rasor, JE Garrus, J Li, PL Cable, C Eberhardt, J Schreiber, S Rush, KW Wood, E Barrett, A Patnaik

October 20 12:30-3:00pmA252 Poster Session A: Therapeutic Agents: Biological

Exhibit Hall C-DPhase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas

JR Infante, G Shapiro, P Witteveen, J Gerecitano, V Ribrag, R Chugh, A Chakraborty, A Matano, X Zhao, S Parasuraman, PA Cassier

October 20 12:30-7:30pmA276 Therapeutic Agents: Small Molecule Kinase Inhibitors

Exhibit Hall C-D

Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686

J Sun, C Karlovich, W Wen, H Wakelee, S Chien, E Mann, P O’Donnell, P Angenendt, R Dziadziuszko, L Horn, DR Spigel, L Sequist, J Soria, B Solomon, DR Camidge, J Goldman, SM Gadgeel, M Raponi, L Wu, K Park

October 21 12:30-3:00pmB25 Poster Session B: Biomarkers

Exhibit Hall C-D

A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors

A El-Khoueiry, C Kurkjian, T Semrad, L Musib, M Gates, S Eppler, I Chang, I Chan, I Rooney, J Bendell

October 21 12:30-3:00pmB75 Poster Session B: Clinical Trials

Exhibit Hall C-DA Phase I study of CC-486 (oral azacitidine) to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of azacitidine administered alone and in combination with carboplatin or ABI-007 (NAB-paclitaxel) in subjects with solid tumors

E Laille, AN Nguyen, G Chen, D Rasco, P LoRusso, DD Von Hoff, J Bendell, P Munster, WJ Edenfield, R Ramanathan, MB Gonzalez, A Blackwood-Chichir, J DiMartino

October 21 12:30-3:00pmB217 Poster Session B: Pharmacokinetics and

PharmacodynamicsExhibit Hall C-D

Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate

RA Graham, S Cheeti, L Salphati, T Lu, C Kurkjian, DV Hoff, J Sachdev, D Juric, J Baselga, H Parmer, J Hsu, JR Infante

October 21 12:30-3:00pmB218 Poster Session B: Pharmacokinetics and

PharmacodynamicsExhibit Hall C-D

A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies

JR Infante, J Tabernero, A Cervantes, S Jalal, HA Burris III, T Macarul-la, A Perez-Fidalgo, R Neuwirth, C Patel, E Gangolli, R Brake, J Sturm, EH Westin, M Gordon

October 21 12:30-3:00pmC252 Poster Session C: Therapeutic Agents: Small Molecule

Kinase InhibitorsExhibit Hall C-D

SM

AACR-NCI-EORTC International Conference onMolecular Targets and Cancer Therapeutics

October 19-23, 2013Hynes Convention Center

Boston, MA, USA

Sarah Cannon Research Institute has 13 abstracts accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

SCRI Lead Author SCRI Co-Author

About the Conference: Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2013 Molecular Targets and Cancer Therapeutics conference will bring together an estimated 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.

The following SCRI Principal Investigators have abstracts accepted for presentation:

SMAACR-NCI-EORTC International Conference on

Molecular Targets and Cancer TherapeuticsOctober 19-23, 2013

Hynes Convention CenterBoston, MA, USA

Howard A. “Skip” Burris, III, M.D. Chief Medical Officer Executive Director, Drug Development Program

John D. Hainsworth, M.D.Chief Scientific Officer

F. Anthony Greco, M.D.Director of Sarah Cannon Cancer Center

Jeffrey R. Infante, M.D.Director, Drug Development Program

Johanna C. Bendell, M.D.Director of GI Cancer Research ProgramAssociate Director, Drug Development

Denise A. Yardley, M.D.Senior Investigator, Breast Cancer Research Program

Kent Shih, M.D.Senior Investigator, Neuro-Oncology Program

Todd Bauer, M.D.Investigator, Drug Development

Suzanne Jones, Pharm.D.Scientific Director, Drug Development Program

Hendrik-Tobias Arkenau, M.D., Ph.DDirector, Drug Development Program Sarah Cannon Research UK

Other SCRI-affilliated investigators presenting at the meeting are:

Manish R. Patel, MDDana S. Thompson, MD